iQ Biosciences

Executive Summary

iQ Biosciences is a US-based contract research organization (CRO) that provides preclinical discovery support for biopharmaceutical companies, with a specialization in immunology. Founded in 2018 and headquartered in Berkeley, the company offers intelligent in-vitro bioservices, including functional assays and high-quality primary immune cells. Its deep immunology expertise enables clients to validate therapeutic binding, mechanism of action, and safety for modalities such as antibodies and CAR-T cells. Positioned in the growing CRO market, iQ Biosciences addresses the increasing demand for outsourced preclinical services, particularly in immuno-oncology. While the company is private and early-stage, its focus on niche immunology services and high-quality biospecimens distinguishes it from larger, generalized CROs. Future growth is expected as biopharma firms continue to rely on specialized partners to accelerate drug development. However, the lack of disclosed financials and its relatively small scale pose risks for rapid expansion. Overall, iQ Biosciences is well-positioned within a favorable market trend, but its success depends on securing key partnerships and scaling operations.

Upcoming Catalysts (preview)

• Q3 2026Signing a strategic partnership with a top-20 pharma company for immunology assay services60% success
• Q4 2026Launch of a new high-throughput screening platform for CAR-T cell therapy validation50% success
• Q2 2026Achieving ISO 9001:2025 certification to enhance quality credentials and attract larger clients75% success